Anti-fibrotic effects of specific-siRNA targeting of the receptor for advanced glycation end products in a rat model of experimental hepatic fibrosis

Cai,Xiao-Gang; Xia,Jin-Rong; Li,Wei-Dong; Lu,Feng-Lin; Liu,Juan; Lu,Qin; Zhi,Hong

doi:10.3892/mmr.2014.2207

Anti-fibrotic effects of specific-siRNA targeting of the receptor for advanced glycation end products in a rat model of experimental hepatic fibrosis

Authors:
- Xiao-Gang Cai
- Jin-Rong Xia
- Wei-Dong Li
- Feng-Lin Lu
- Juan Liu
- Qin Lu
- Hong Zhi
View Affiliations

Affiliations: Department of Gastroenterology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu 210009, P.R. China
Published online on: May 2, 2014 https://doi.org/10.3892/mmr.2014.2207
Pages: 306-314

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Since the receptor for advanced glycation end products (RAGE)-ligand axis has been demonstrated to be important in fibrogenesis, rat models may be used to assess whether specific small interfering RNAs (siRNAs) that target RAGE are able to reduce the progression of hepatic fibrosis. However, the effect of RAGE-targeted siRNA on established hepatic fibrosis remains to be elucidated. In the present study, RAGE-specific siRNA expression vectors were constructed prior to the animal experiment. Sprague-Dawley rats were treated initially with olive oil (2 ml/kg) or 50% CCl4 (2 ml/kg; CCl4/olive oil=1:1) twice per week for six weeks to generate the fibrosis model. The rats were then treated with phosphate‑buffered saline, a RAGE-specific siRNA expression vector, at different doses or a non-specific siRNA expression vector twice weekly via tail vein injection for up to six weeks, and were sacrificed at week two, four or six. Compared with the control groups, RAGE‑specific siRNA therapy significantly decreased RAGE mRNA and protein expression in rat livers (P<0.01). Following six weeks of RAGE gene-silencing treatment, the liver function, which was assessed by analyzing serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and total bilirubin (TBIL), improved to varying degrees (P<0.01). The expression of nuclear factor-κB (NF-κB) significantly decreased following RAGE gene‑silencing therapy (P<0.01). In addition, the serum levels of inflammatory cytokines, including tumor necrosis factor‑α (TNF-α) and interleukin-6 (IL-6), and extracellular matrix (ECM) components, including hyaluronic acid (HA), laminin (LN) and procollagen type III (PCIII) also decreased (P<0.01). Furthermore, the expression of α-smooth muscle actin (α-SMA) and collagen I, which indicate the activation of hepatic stellate cells (HSCs), were downregulated following RAGE gene-silencing therapy (P<0.01). Furthermore, the inflammatory activity grade and fibrosis stage of rat livers also significantly improved compared with the control groups following RAGE gene-silencing therapy. Specific targeting of RAGE using siRNA may inhibit RAGE gene expression effectively in the rat hepatic fibrosis model and attenuate the progression of established hepatic fibrosis. This therapeutic effect may be mediated via inhibition of the expression of NF-κB. These findings suggest that RAGE may be a new target to prevent hepatic fibrosis.

View Figures

View References

1	Anthony PP, Ishak KG, Nayak NC, Poulsen HE, Scheuer PJ and Sobin LH: The morphology of cirrhosis. Recommendations on definition, nomenclature, and classification by a working group sponsored by the World Health Organization. J Clin Pathol. 31:395–414. 1978. View Article : Google Scholar : PubMed/NCBI
2	Friedman SL, Roll FJ, Boyles J and Bissell DM: Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci USA. 82:8681–8685. 1985. View Article : Google Scholar : PubMed/NCBI
3	Rippe RA: Life or death: the fate of the hepatic stellate cell following hepatic injury. Hepatology. 27:1447–1448. 1998. View Article : Google Scholar : PubMed/NCBI
4	Brandão DF, Ramalho LN, Ramalho FS, Zucoloto S, de Martinelli AL and de Silva OC: Liver cirrhosis and hepatic stellate cells. Acta Cir Bras. 21(Suppl 1): 54–57. 2006.
5	Lee UE and Friedman SL: Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol. 25:195–206. 2011. View Article : Google Scholar
6	Neeper M, Schmidt AM, Brett J, et al: Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem. 267:14998–15004. 1992.PubMed/NCBI
7	Sparvero LJ, Asafu-Adjei D, Kang R, et al: RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med. 7:172009. View Article : Google Scholar : PubMed/NCBI
8	Schmidt AM, Yan SD, Yan SF and Stern DM: The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta. 1498:99–111. 2000. View Article : Google Scholar : PubMed/NCBI
9	Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM and Wautier JL: Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab. 280:E685–E694. 2001.PubMed/NCBI
10	Mohamed AK, Bierhaus A, Schiekofer S, Tritschler H, Ziegler R and Nawroth PP: The role of oxidative stress and NF-kappaB activation in late diabetic complications. Biofactors. 10:157–167. 1999. View Article : Google Scholar : PubMed/NCBI
11	Fehrenbach H, Weiskirchen R, Kasper M and Gressner AM: Up-regulated expression of the receptor for advanced glycation end products in cultured rat hepatic stellate cells during transdifferentiation to myofibroblasts. Hepatology. 34:943–952. 2001. View Article : Google Scholar : PubMed/NCBI
12	Brett J, Schmidt AM, Yan SD, et al: Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol. 143:1699–1712. 1993.PubMed/NCBI
13	Lohwasser C, Neureiter D, Popov Y, Bauer M and Schuppan D: Role of the receptor for advanced glycation end products in hepatic fibrosis. World J Gastroenterol. 15:5789–5798. 2009. View Article : Google Scholar : PubMed/NCBI
14	Guimarães EL, Empsen C, Geerts A and van Grunsven LA: Advanced glycation end products induce production of reactive oxygen species via the activation of NADPH oxidase in murine hepatic stellate cells. J Hepatol. 52:389–397. 2010.PubMed/NCBI
15	Xia JR, Liu NF and Zhu NX: Specific siRNA targeting the receptor for advanced glycation end products inhibits experimental hepatic fibrosis in rats. Int J Mol Sci. 9:638–661. 2008. View Article : Google Scholar
16	Barouch DH, Liu J, Li H, et al: Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature. 482:89–93. 2012. View Article : Google Scholar : PubMed/NCBI
17	Desmet VJ, Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW and Wollman J: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. [Hepatology 1981;1:431–435]. J Hepatol. 38:382–386. 2003.PubMed/NCBI
18	Ishak K, Baptista A, Bianchi L, et al: Histological grading and staging of chronic hepatitis. J Hepatol. 22:696–699. 1995. View Article : Google Scholar : PubMed/NCBI
19	Karin M and Lin A: NF-kappaB at the crossroads of life and death. Nat Immunol. 3:221–227. 2002. View Article : Google Scholar : PubMed/NCBI
20	Luo JL, Kamata H and Karin M: The anti-death machinery in IKK/NF-kappaB signaling. J Clin Immunol. 25:541–550. 2005. View Article : Google Scholar : PubMed/NCBI
21	Haskill S, Beg AA, Tompkins SM, et al: Characterization of an immediate-early gene induced in adherent monocytes that encodes I kappa B-like activity. Cell. 65:1281–1289. 1991. View Article : Google Scholar : PubMed/NCBI
22	Beg AA, Finco TS, Nantermet PV and Baldwin AS Jr: Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation. Mol Cell Biol. 13:3301–3310. 1993.PubMed/NCBI
23	Aggarwal BB: Nuclear factor-kappaB: the enemy within. Cancer Cell. 6:203–208. 2004.PubMed/NCBI
24	Yan SD, Schmidt AM, Anderson GM, et al: Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem. 269:9889–9897. 1994.PubMed/NCBI
25	Yan SD, Stern D and Schmidt AM: What’s the RAGE? The receptor for advanced glycation end products (RAGE) and the dark side of glucose. Eur J Clin Invest. 27:179–181. 1997.
26	Li J and Schmidt AM: Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem. 272:16498–16506. 1997. View Article : Google Scholar : PubMed/NCBI
27	Hellerbrand C, Jobin C, Licato LL, Sartor RB and Brenner DA: Cytokines induce NF-kappaB in activated but not in quiescent rat hepatic stellate cells. Am J Physiol. 275:G269–G278. 1998.PubMed/NCBI
28	Hellerbrand, Wang SC, Tsukamoto H, Brenner DA and Rippe RA: Expression of intracellular adhesion molecule 1 by activated hepatic stellate cells. Hepatology. 24:670–676. 1996. View Article : Google Scholar : PubMed/NCBI
29	Liu C, Tao Q, Sun M, et al: Kupffer cells are associated with apoptosis, inflammation and fibrotic effects in hepatic fibrosis in rats. Lab Invest. 90:1805–1816. 2010. View Article : Google Scholar : PubMed/NCBI
30	Senoo H, Yoshikawa K, Morii M, Miura M, Imai K and Mezaki Y: Hepatic stellate cell (vitamin A-storing cell) and its relative - past, present and future. Cell Biol Int. 34:1247–1272. 2010. View Article : Google Scholar : PubMed/NCBI
31	Otogawa K, Ogawa T, Shiga R, Ikeda K and Kawada N: Induction of tropomyosin during hepatic stellate cell activation and the progression of liver fibrosis. Hepatol Int. 3:378–383. 2009. View Article : Google Scholar : PubMed/NCBI